Table 3.
Treatment modalities in patients with VITT after ChAdOx1 nCoV-19 vaccination according to outcome
| Treatment | Total patients (n = 64a) | Survivors (n = 40) | Non-survivors (n = 23) | P-value |
|---|---|---|---|---|
| Treatment received | ||||
| Heparins | 26/39 (66.7%) | 17/23 (73.9%) | 9/16 (56.3%) | 0.312 |
| Unfractionated heparin | 10/39 (25.6%) | 6/23 (26.1%) | 4/16 (25.0%) | 1.000 |
| Low molecular weight heparin | 11/39 (28.2%) | 7/23 (30.4%) | 4/16 (25.0%) | 1.000 |
| Fondaparinux | 6/39 (15.4%) | 5/23 (21.7%) | 1/16 (6.3%) | 0.370 |
| Steroids | 13/41 (31.7%) | 9/24 (37.5%) | 4/16 (25.0%) | 0.503 |
| Prednisolone | 5/41 (12.2%) | 4/24 (16.7%) | 1/16 (6.3%) | 0.631 |
| Methylprednisolone | 6/41 (14.6%) | 4/24 (16.7%) | 2/16 (12.5%) | 1.000 |
| Dexamethasone | 4/41 (9.8%) | 3/24 (12.5%) | 1/16 (6.3%) | 0.638 |
| Transfusion | ||||
| Intravenous immunoglobulin | 18/41 (43.9%) | 13/24 (54.2%) | 5/16 (31.3%) | 0.203 |
| Platelet | 8/41 (19.5%) | 2/24 (8.3%) | 6/16 (37.5%) | 0.042 |
| Red blood cell | 1/41 (2.4%) | 0/24 (0.0%) | 1/16 (6.3%) | 0.400 |
| Fibrinogen concentrate | 1/41 (2.4%) | 1/24 (4.2%) | 0/16 (0.0%) | 1.000 |
| Plasmapheresis | 1/41 (2.4%) | 1/24 (4.2%) | 0/16 (0.0%) | 1.000 |
| Surgery | 12/41 (29.3%) | 5/24 (20.8%) | 7/16 (43.8%) | 0.166 |
| Neurosurgery | 8/41 (19.5%) | 1/24 (4.2%) | 7/16 (43.8%) | 0.004 |
| Bowel resection | 3/41 (7.3%) | 3/24 (12.5%) | 0/16 (0.0%) | 0.262 |
| Thrombectomy | 2/41 (4.9%) | 1/24 (4.2%) | 1/16 (6.3%) | 1.000 |
| Tissue plasminogen activator | 1/41 (2.4%) | 1/24 (4.2%) | 0/16 (0.0%) | 1.000 |
| Non-heparin anticoagulants | 14/41 (34.1%) | 13/24 (54.2%) | 1/16 (6.3%) | 0.002 |
| Direct oral anticoagulant | 6/41 (14.6%) | 5/24 (20.8%) | 1/16 (6.3%) | 0.373 |
| Direct thrombin inhibitor | 7/41 (17.1%) | 7/24 (29.2%) | 0/16 (0.0%) | 0.029 |
| Eculizumab | 2/41 (4.9%) | 2/24 (8.3%) | 0/16 (0.0%) | 0.508 |
a
One patient had an unknown outcome.